Abstract
Cutaneous lymphomas are rare and, although some are a manifestation of systemic lymphoma, the majority arise primarily from the skin. These primary cutaneous lymphomas comprise both T- and B-cell subtypes and represent a wide spectrum of disorders, which at times can be difficult to diagnose and classify. Classical therapeutic strategies include topical corticosteroids, phototherapy, radiotherapy, retinoids, extracorporeal photopheresis, topical chemotherapy, systemic chemotherapy and biological response modifiers. Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin-12 and monoclonal antibodies such as alemtuzumab and rituximab.
MeSH terms
-
Administration, Topical
-
Adrenal Cortex Hormones / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Biopsy, Needle
-
Combined Modality Therapy
-
Education, Medical, Continuing
-
Female
-
Humans
-
Immunohistochemistry
-
Immunologic Factors / therapeutic use
-
Lymphoma, T-Cell, Cutaneous / mortality
-
Lymphoma, T-Cell, Cutaneous / pathology*
-
Lymphoma, T-Cell, Cutaneous / therapy*
-
Male
-
Mycosis Fungoides / mortality
-
Mycosis Fungoides / pathology
-
Mycosis Fungoides / therapy
-
Neoplasm Staging
-
Phototherapy / methods
-
Prognosis
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Sezary Syndrome / mortality
-
Sezary Syndrome / pathology
-
Sezary Syndrome / therapy
-
Skin Neoplasms / mortality
-
Skin Neoplasms / pathology*
-
Skin Neoplasms / therapy*
-
Survival Analysis
-
Treatment Outcome
Substances
-
Adrenal Cortex Hormones
-
Immunologic Factors